# First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial

> **NCT05574998** · PHASE2 · UNKNOWN · sponsor: **Qianfoshan Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Recombinant human endostatin (Endostar)

## Key facts

- **NCT ID:** NCT05574998
- **Lead sponsor:** Qianfoshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-01
- **Primary completion:** 2024-02-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05574998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05574998, "First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05574998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*